The 2014 Alzheimer's Disease Congress

London, London
Monday, 23 June 2014

This event will be held at The O2,  a large entertainment district on the Greenwich peninsula in South East London, England.
The 2014 Alzheimer's Disease Congress
Monday, 23 June 2014 09:30 -
Wednesday, 25 June 2014 17:00

Cineworld: The O2
Peninsula Square
SE10 0DX
United Kingdom

Map and Directions

This three day event will discuss aspects of  Alzheimer's Disease development and treatment in an informal academic setting. This year there are three main topics for discussion
  1. Biomarker Discovery and Assay Development 
  2. Prevention Strategies and Vaccine Development 
  3. Drug Discovery and Development 
With plenty of opportunity  for networking and debate, this informal international  meeting will bring you up to date with current research and thinking regarding Alzheimer's Disease.
This event  has CPD accreditation and 
an open oral and poster session.  Abstracts can be submitted on any subject related to Alzheimer's Disease

The deadline for abstract submissions for oral presentation is March 10th 2014.  Abstracts for poster presentation only can be submitted up to two weeks before the event.  
You can download the instructions for authors at

Program Outline

Day 1: Biomarker Discovery and Assay Development
Currently, there are many biomarkers for diagnosis of Alzheimer's disease. However most of them do not provide consistent results.  This session will discuss current research aimed at obtaining reliable biomarkers which could be used to diagnose Alzheimer's disease at very early stage and also to provide objective and reliable measures of disease progress.

Day 2:  Prevention Strategies and Vaccine Development 
This session will discuss current research into Alzheimer's Disease prevention including vaccine development. There will be plenty of opportunity for discussion and debate.

Day 3:  Drug Discovery and Development
There are currently no treatments that will stop or reverse the progress of Alzheimer’s disease. With an aging population and increasing number of people with Alzheimer’s, the need to develop ways to halt and treat the disease have become paramount.  This session will discuss current research into Alzheimer’s drug discovery and development including analysis of current clinical trials

Talks include

  • SemiAlloGeneic Vaccines for Alzheimer's Disease, Professor Mark S. Kindy, Medical University of South Carolina, USA
  • New era in AD drug design: intracellular and exosomal targets, Dr Botond Penke, Professor,  University of Szeged, Department of Medical Chemistry, Hungary
  • Why have we failed to cure AD?, Professor Amos Korczyn, Professor Emeritus, Tel-Aviv University Medical School, Israel
  • What did we learn from the first clinical trial of Aβ immunotherapy?, Dr Delphine Boche, Senior lecturer (Associate Professor), University of Southampton, UK
  • Combining drug-like fragments in multitarget new chemical entities for Alzheimer’s disease, Professor Andrea Cavalli, University of Bologna and Italian Institute of Technology, Italy
  • The role of herpes simplex virus type 1 in Alzheimer’s disease, Professor Ruth Frances Itzhaki, University of Manchester, Manchester, UK
  • Is AD A Medical Notion of Dementia Worth Keeping in Neuroscience?, Professor Fred C. C. Peng, Ph.D. Affiliation: Department of Neurosurgery and Neurological Institute, Taipei Veterans General Hospital, Taiwan
  • The biomarkers assessment in a Memory Clinic : is there any added value?, Professor Adrian Ivanoiu, MD, PhD, neurologist, Saint Luc University Hospital & Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium
  • How to Prevent Dementia and Alzheimer's, Dr Allen J. Orehek, Innovator/Physician, Dementia Prevention Center, USA
  • Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease, Dr Željko M. Svedružić, Assistant Professor, Faculty of Medicine, and Department of Biotechnolgy, Univeristy of Rijeka, Croatia
  • Regulatory T cells as new targets for immunotherapy in Alzheimer's disease?, Dr Guillaume Dorothee, Hôpital Saint-Antoine, Paris, France
  • Activities of daily living: a new approach to discovering Alzheimer therapies, Dr Robert Deacon, UK
  • Cerebrospinal fluid Presenilin-1: a potential new biomarker for Alzheimer’s disease, Dr Javier Sáez-Valero, Professor and Group Leader, Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, & Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
  • Investigation of novel functional and metabolic MRI biomarkers for  the preclinical assessment of taupathology in AD, Dr Niall Colgan, Research Associate, UCL Centre for Advanced Biomedical Imaging, London UK
  • Alzheimer's disease in Down's syndrome -an ideal model for biomarker discovery? Dr Shahid Zaman, Affiliated Lecturer & Consultant Psychiatrist, University of Cambridge & NHS, UK
  • Amyloid hypothesis for AD: Insight from single molecule experiments and computational analyses, Professor Yuri Lyubchenko, University of Nebraska Medical Center, USA
  • Going beyond Preclinical Animal Models : Quantitative Systems Pharmacology to support Alzheimer’s Disease Research & Development Dr Hugo Geerts, Chief Scientific Officer,  In Silico Biosciences, USA
  • Moving DNA Immunization toward an Alzheimer’s disease clinical trial, Prof. David H. Cribbs, Professor and Associate Director,  Institute for Memory Impairment and Neurological Disorders, Department of Neurology, Co-leader, Neuropathology Core, UCI Alzheimer’s Disease Research Center (ADRC), University of California, Irvine, CA, USA
  • Multiscale computational approach illuminating novel common pathways between diabetes and AD
    Giulio Maria Pasinetti, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA

Additional Confirmed Speakers
  • Dr. Kailas Dashrath Sonawane, Head Department of Microbiology, Shivaji University, Maharashtra, India

Keywords: biomarkers, biomarker,neurochemical, Alzheimer's disease,blood plasma,Amyloid beta,BACE1,Soluble Aβ precursor protein,Beta amyloid antibodies, Amyloid hypothesis; Prevention; Brain Aging; Dementia; , biomarkers,  mild cognitive impairment, Memory Clinic, Tau, MRI, biomarker, imaging, Alzheimers, , Cerebrospinal fluid, Biomarker, Presenilin, γ-Secretase,Amyloid beta,,Immunotherapy,Passive immunotherapy, MPC-7869,γ-secretase,AL-108,PBT2 ,Immunotherapy,Passive immunotherapy,AN-1792,Gamma secretase,LY451039,Tarenflurbil,PBT2 ,Simvastatin,Allopregnanolone,Angiotensin ,Cannabinoids,Methylthioninium chloride, immunotherapy, neuroinflammation, neurodegeneration, γ-secretase, amyloid, enzyme-mechanisam, FAD mutations, Burrowing, hippocampus, nesting, hoarding, marble, dementia, brain ageing, alzheimer's, intracellular Abeta, prionoid, exosome, cell-to-cell spreading, Down's syndrome, Amyloid, [11C]-PiB-PET, Alzheimer's disease; herpes simplex virus type 1; beta amyloid; AD-like tau; antiviral agents, Fischer's Disease, Dementia, MCI, Auguste's brain atrophy, Translational disconnect, Systems Pharmacology, Trial Failure analysis, Alzheimer's disease, adaptive immunity, regulatory T cells, neuroinflammation, immunotherapy, Alzheimer's disease; Biomarkers; Cerebrospinal fluid, Mild cognitive impairment, Immunotherapy, antibody, autoimmune.


Contact Details

Payment Instructions

  • Payment must be received prior to the meeting

    Credit card
    You can pay during your online registration using your credit card. The information taken will be by secure server. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered 

    You can either use your Paypal account or click on the no account link to pay directly by credit or debit card

    If you wish to pay by purchase order or bank transfer, please contact

        Linked in   
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5 4LQ. 

© 2020
Quick, easy and affordable online event registration and event management software for all event sizes.